Suppr超能文献

通过放血疗法减少骨髓移植治愈的地中海贫血患者的铁过载。意大利移植地中海贫血患者放血治疗合作组。

Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.

作者信息

Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P

机构信息

Divisione di Ematologia e Centro Trapianto Midollo Osseo di Muraglia, and Azienda Ospedale di Pesaro, Italy.

出版信息

Blood. 1997 Aug 1;90(3):994-8.

PMID:9242528
Abstract

In thalassemia after successful bone marrow transplantation (BMT), iron overload remains an important cause of morbidity. After BMT, patients have normal erythropoiesis capable of producing a hyperplastic response to phlebotomy so that this procedure can be contemplated as a method of mobilizing iron from overloaded tissues. A phlebotomy program (6 mL/kg blood withdrawal at 14-day intervals) was proposed to 48 patients with prolonged follow-up (range, 2 to 7 years) after BMT. Seven patients were not submitted to the program (five because of refusal and two because of reversible side effects). The remaining 41 patients (mean age, 16 +/- 2.9 years) were treated for a mean period of 35 +/- 18 months. All were evaluated before and after 3 +/- 0.6 years of follow-up. Values are expressed as mean +/- standard deviation (SD) or as median with a range (25 to 75 percentile). Serum ferritin decreased from 2,587 (2,129 to 4,817) to 417 (210 to 982) microg/L (P < .0001), total transferrin increased from 2.34 +/- 0.37 to 2.7 +/- 0.58 g/L (P = .0001), transferrin saturation decreased from 90% +/- 14% to 50% +/- 29% (P < .0001). Liver iron concentration evaluated on liver biopsy specimens decreased from 20.8 (15.5 to 28.1) to 4.2 (1.6 to 14.6) mg/g dry weight (P < .0001). Aspartate transaminase decreased from 2.7 +/- 2 to 1.1 +/- 0.6 (P < .0001) and alanine transaminase from 5.2 +/- 3.4 to 1.7 +/- 1.2 (P < .0001) times the upper level of normality. The Knodell score for liver histological activity decreased from 6.9 +/- 3 to 4.9 +/- 2.8 (P < .0001). These data indicate that phlebotomy is safe, efficient, and widely applicable to ex-thalassemics after BMT.

摘要

在成功进行骨髓移植(BMT)后的地中海贫血患者中,铁过载仍然是发病的重要原因。BMT后,患者的红细胞生成正常,能够对放血产生增生反应,因此可以考虑将放血作为一种从过载组织中动员铁的方法。我们对48例BMT后随访时间延长(范围为2至7年)的患者提出了一个放血方案(每14天抽取6 mL/kg血液)。7例患者未接受该方案(5例因拒绝,2例因可逆性副作用)。其余41例患者(平均年龄16±2.9岁)接受治疗的平均时间为35±18个月。所有患者在随访3±0.6年后进行了评估。数值以平均值±标准差(SD)表示,或以中位数及范围(第25至75百分位数)表示。血清铁蛋白从2587(2129至4817)降至417(210至982)μg/L(P <.0001),总转铁蛋白从2.34±0.37增至2.7±0.58 g/L(P =.0001),转铁蛋白饱和度从90%±14%降至50%±29%(P <.0001)。肝活检标本评估的肝脏铁浓度从20.8(15.5至28.1)降至4.2(1.6至14.6)mg/g干重(P <.0001)。天冬氨酸转氨酶从2.7±2降至1.1±0.6(P <.0001),丙氨酸转氨酶从5.2±3.4降至1.7±1.2(P <.0001)倍正常上限。肝脏组织学活性的Knodell评分从6.9±3降至4.9±2.8(P <.0001)。这些数据表明,放血对BMT后的地中海贫血患者是安全、有效的,且广泛适用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验